BPC-157 and TB-500 Research Guide: What the Science Shows So Far
This guide is for research and educational purposes only. Nothing in this article is medical advice, and all products referenced are sold strictly for laboratory research use only.
The short version: BPC-157 and TB-500 are two of the most studied peptides in tissue-repair research — but nearly all of the evidence comes from animal models, not human trials. BPC-157 is a 15-amino-acid fragment derived from a stomach protein, studied for tendon, muscle, gut, and wound healing. TB-500 is a synthetic version of the naturally occurring repair protein Thymosin Beta-4, studied for cell migration, wound healing, and cardiac repair. Researchers often study them together — the combination nicknamed the “Wolverine stack” — on the theory that their repair mechanisms complement each other. Neither is FDA-approved, and neither has published human clinical trials.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a pentadecapeptide — a chain of 15 amino acids — derived from a protein found in human gastric juice. It was first described by researchers studying the stomach’s own protective mechanisms, which is why much of the early work focused on gut and intestinal healing.
In the published literature, BPC-157 has been studied almost entirely in rodents (rats and mice). Reported research areas include:
- Tendon and ligament healing (including Achilles tendon models)
- Muscle and bone repair
- Gastric ulcers and intestinal injury models
- Liver protection in toxin models
- Neuroprotection in brain injury models
Proposed mechanisms include promotion of angiogenesis (new blood vessel formation), modulation of growth-factor signaling, interaction with the nitric oxide system, and anti-inflammatory effects. The exact pathways remain under investigation.
Critically: there are no published human clinical trials of BPC-157. Everything reported comes from preclinical animal work.
What Is TB-500?
TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid peptide that occurs naturally in the human body and plays a role in cell repair and regeneration. TB-500 replicates the active region of that larger protein.
Animal research on TB-500 / Thymosin Beta-4 has covered:
- Wound and skin healing
- Cardiac tissue repair (animal models of heart injury)
- Corneal and eye injuries
- Anti-inflammatory effects
- Hair growth (animal models)
Its best-characterized mechanism is regulation of actin — the protein cells use to move — which promotes cell migration toward injury sites, alongside pro-angiogenic and anti-inflammatory signaling.
Like BPC-157: no published human clinical trials, and not FDA-approved.
The “Wolverine Stack”: Why Researchers Combine Them
The nickname comes from the comic-book character’s rapid healing. The research rationale for studying them together is mechanistic complementarity:
- BPC-157 is investigated more for localized healing signaling and blood-vessel formation at injury sites
- TB-500 is investigated more for systemic effects — helping repair cells migrate to where they are needed
An honest caveat: there is very little published research on the combination itself. The stack’s popularity comes from research communities extrapolating from the individual compounds’ animal data, not from combination trials. Treat combination claims as theoretical.
BPC-157 vs. TB-500
| BPC-157 | TB-500 | |
|---|---|---|
| Full name | Body Protection Compound-157 | Synthetic Thymosin Beta-4 fragment |
| Size | 15 amino acids | Active fragment of a 43-amino-acid protein |
| Origin | Derived from human gastric juice protein | Synthetic copy of a natural human repair protein |
| Primary research focus | Tendon, gut, wound healing | Cell migration, wound, cardiac repair |
| Key proposed mechanism | Angiogenesis, growth-factor modulation | Actin regulation, cell migration |
| Human trials | None published | None published |
| Regulatory status | Not FDA-approved; research use only | Not FDA-approved; research use only |
Research Status in 2026
Both compounds remain strictly preclinical: studied in cell cultures and animals, with no published human efficacy trials and no FDA approval for any indication. Any product sold online as BPC-157 or TB-500 is an unregulated research chemical, not a medicine.
One regulatory note researchers should know: both compounds are prohibited in competitive sport under World Anti-Doping Agency (WADA) rules. Athletes subject to testing should be aware.
Handling and Storage (Laboratory Context)
Like most synthetic peptides, BPC-157 and TB-500 for research are supplied as a lyophilized (freeze-dried) powder. Standard laboratory practice is to store lyophilized peptides frozen for long-term stability (refrigerated for shorter-term storage), protected from light and moisture. Once reconstituted with bacteriostatic water for laboratory use, solutions are typically kept refrigerated and used within laboratory-defined time windows. Always follow your institution’s protocols.
Evaluating Research-Grade BPC-157 and TB-500: A Quality Checklist
Because the research-peptide market has no mandatory batch testing, quality is opaque unless the vendor proves it. Before sourcing any compound for research, verify:
- Third-party testing — an independent HPLC and mass-spectrometry certificate of analysis (COA) for the specific batch
- Stated purity — research-grade peptides are typically ≥99% pure
- Lyophilized form — sealed vials, properly labeled
- Clear storage guidance — the vendor should document how the product should be kept
- Vendor transparency — a real business location and reachable support
Frequently Asked Questions
What is the Wolverine stack?
The nickname for researching BPC-157 and TB-500 together, based on the theory that their tissue-repair mechanisms complement each other. Direct research on the combination is very limited.
Are BPC-157 and TB-500 FDA approved?
No. Neither is approved for any medical use, and neither has published human clinical trials.
What is the difference between BPC-157 and TB-500?
Different origins and somewhat different research emphases: BPC-157 (a stomach-derived fragment) is studied more for tendon, gut, and localized healing; TB-500 (a Thymosin Beta-4 fragment) is studied more for cell migration and systemic repair signaling. Both are preclinical only.
Have these been tested in humans?
No published human efficacy trials exist for either compound. All reported findings come from animal and cell studies.
Are they legal?
They are sold as research chemicals for laboratory use only — not as medicines, and not for human or veterinary use. Both are banned in WADA-tested competitive sport.
Where can researchers source BPC-157 and TB-500?
See our research-grade Wolverine blend (BPC-157 + TB-500) →. Sold strictly for laboratory research use only; not for human or veterinary use.
Disclaimer: This article is educational content about research compounds. It is not medical advice, does not recommend any use in humans or animals, and makes no therapeutic claims. Diamond Lab Peptides products are sold for in-vitro laboratory research use only.
